Terms: = Ovarian cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
124 results:
1. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
Cai X; Lin J; Liu L; Zheng J; Liu Q; Ji L; Sun Y
BMC Cancer; 2024 Apr; 24(1):515. PubMed ID: 38654239
[TBL] [Abstract] [Full Text] [Related]
2. Targeting Tryptophan Catabolism in ovarian cancer to Attenuate Macrophage Infiltration and pd-l1 Expression.
Crump LS; Floyd JL; Kuo LW; Post MD; Bickerdike M; O'Neill K; Sompel K; Jordan KR; Corr BR; Marjon N; Woodruff ER; Richer JK; Bitler BG
Cancer Res Commun; 2024 Mar; 4(3):822-833. PubMed ID: 38451784
[TBL] [Abstract] [Full Text] [Related]
3. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
[TBL] [Abstract] [Full Text] [Related]
4. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract] [Full Text] [Related]
5. Construction and validation of molecular subtype and signature of immune cell-related telomeric genes and prediction of prognosis and immunotherapy efficacy in ovarian cancer patients.
Ling L; Li B; Wu H; Zhang K; Li S; Ke B; Zhu Z; Liu T; Liu P; Zhang B
J Gene Med; 2024 Jan; 26(1):e3606. PubMed ID: 38282157
[TBL] [Abstract] [Full Text] [Related]
6. pd-l1 and PD-1 Expression in Early Stage Uterine Endometrioid Carcinoma.
An HJ; Yang JW; Kim MH; Song DH
In Vivo; 2024; 38(1):246-252. PubMed ID: 38148043
[TBL] [Abstract] [Full Text] [Related]
7. Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with αpdl1 in ovarian cancer.
Wang S; Liu Y; Xiao H; Chen Z; Yang X; Yin J; Li Y; Yuan C; Yan S; Chen G; Gao Q; Kong B; Sun C; Song K
Cell Death Dis; 2023 Nov; 14(11):775. PubMed ID: 38012150
[TBL] [Abstract] [Full Text] [Related]
8. Expression of EGFR, pd-l1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
[TBL] [Abstract] [Full Text] [Related]
9. C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer.
Zhang C; Cao K; Yang M; Wang Y; He M; Lu J; Huang Y; Zhang G; Liu H
Oncoimmunology; 2023; 12(1):2261242. PubMed ID: 37791232
[TBL] [Abstract] [Full Text] [Related]
10. Establishment and validation of an immune infiltration predictive model for ovarian cancer.
Song Z; Zhang J; Sun Y; Jiang Z; Liu X
BMC Med Genomics; 2023 Sep; 16(1):227. PubMed ID: 37759229
[TBL] [Abstract] [Full Text] [Related]
11. Necroptosis-related regulatory pattern and scoring system for predicting therapeutic efficacy and prognosis in ovarian cancer.
Lai H; Guo Y; Wu L; Yusufu A; Zhong Q; Liao Z; Ma J; Shi W; Yang G; Chen S
Cancer Rep (Hoboken); 2023 Oct; 6(10):e1893. PubMed ID: 37681751
[TBL] [Abstract] [Full Text] [Related]
12. A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance.
Chen L; Gao W; Lin L; Sha C; Li T; Chen Q; Wei H; Yang M; Xing J; Zhang M; Zhao S; Xu W; Li Y; Long L; Zhu X
J Ovarian Res; 2023 Sep; 16(1):186. PubMed ID: 37674251
[TBL] [Abstract] [Full Text] [Related]
13. Prevalence and prognostic role of pd-l1 in patients with gynecological cancers: A systematic review and meta-analysis.
Fu H; Fu Z; Mao M; Si L; Bai J; Wang Q; Guo R
Crit Rev Oncol Hematol; 2023 Sep; 189():104084. PubMed ID: 37536446
[TBL] [Abstract] [Full Text] [Related]
14. The Prognostic Significance of Tumor-Infiltrating Lymphocytes, pd-l1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous ovarian Carcinoma-A Study by the Spanish Group for ovarian cancer Research (GEICO).
Pizarro D; Romero I; Pérez-Mies B; Redondo A; Caniego-Casas T; Carretero-Barrio I; Cristóbal E; Gutiérrez-Pecharromán A; Santaballa A; D'Angelo E; Hardisson D; Vieites B; Matías-Guiu X; Estévez P; Guerra E; Prat J; Poveda A; López-Guerrero JA; Palacios J
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446361
[TBL] [Abstract] [Full Text] [Related]
15. EFEMP2 upregulates pd-l1 expression via EGFR/ERK1/2/c-Jun signaling to promote the invasion of ovarian cancer cells.
Shen X; Jin X; Fang S; Chen J
Cell Mol Biol Lett; 2023 Jul; 28(1):53. PubMed ID: 37420173
[TBL] [Abstract] [Full Text] [Related]
16. Clinical Outcome and Morphology-Based Analysis of p53 Aberrant and Mismatch Repair Protein-Deficient ovarian Clear Cell Carcinoma and Their Association With p16, HER2, and pd-l1 Expression.
Wilkins R; Lin LH; Xia R; Shiomi T; Zamuco RD; Shukla PS
Am J Clin Pathol; 2023 Nov; 160(5):466-476. PubMed ID: 37415414
[TBL] [Abstract] [Full Text] [Related]
17. Landscape of PCOS co-expression gene and its role in predicting prognosis and assisting immunotherapy in endometrial cancer.
Zhang Y; Hu Y; Yu J; Xie X; Jiang F; Wu C
J Ovarian Res; 2023 Jul; 16(1):129. PubMed ID: 37393293
[TBL] [Abstract] [Full Text] [Related]
18. Identification of immune-related gene signature for predicting prognosis in uterine corpus endometrial carcinoma.
Song S; Gu H; Li J; Yang P; Qi X; Liu J; Zhou J; Li Y; Shu P
Sci Rep; 2023 Jun; 13(1):9255. PubMed ID: 37286702
[TBL] [Abstract] [Full Text] [Related]
19. pd-l1 expression, morphology, and molecular characteristic of a subset of aggressive uterine tumor resembling ovarian sex cord tumor and a literature review.
Xiong SP; Luo RZ; Wang F; Yang X; Lai JP; Zhang C; Liu LL
J Ovarian Res; 2023 May; 16(1):102. PubMed ID: 37221583
[TBL] [Abstract] [Full Text] [Related]
20. Low plasma pd-l1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
[TBL] [Abstract] [Full Text] [Related]
[Next]
